Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 336-342

  Lehr, Hans Anton ^a   Rochat, Candice ^a   Schaper, Cornelia ^b   Nobile, Antoine ^a   Shanouda, Sherien ^a   Vijgen, Sandrine ^a   Gauthier, Arnaud ^a   Obermann, Ellen ^c   Leuba, Susana ^a   Schmidt, Marcus ^b   C, Curzio Ruegg ^d   Delaloye, Jean Francois ^e   Simiantonaki, Nectaria ^f   Schaefer, Stephan C ^g  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF FRIBOURG   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Institute of Pathology   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

biopsy; breast cancer; cell proliferation; metaphase; mitotic figure count; proliferative activity; resection specimen

Indexed keywords

ADULT; ANAPHASE; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER INVASION; CANCER SURGERY; CELL CYCLE ARREST; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METAPHASE; MITOSIS; MITOTIC FIGURE COUNT; PRIORITY JOURNAL; TUMOR CELL;

EID: 84875169251     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.140     Document Type: Article

References (25)

1. Amadori D, Volpi A, Maltoni R, et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997;43:7-14.
2. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
3. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
4. Elston EW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with longterm follow-up. Histopathology 1993;19:403-410.
5. Dahlstrom JE, Sutton S, Jain S. Histological precision of stereotactic core biopsy in diagnosis of malignant and premalignant breast lesions. Histopathology 1996;28:537-541.
6. Di Loreto C, Puglisi F, Rimondi G, et al. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer 1996;32A: 1693-1700.
7. Denley H, Pinder SE, Elston CW, et al. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001;54:20-24.
8. Sharifi S, Peterson MK, Baum JK, et al. Assessment of pathologic prognostic factors in breast core needle biopsies. Mod Pathol 1999;12:941-945.
9. Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 2003;27:11-15.
10. Badoual C, Maruani A, Ghorra C, et al. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast 2005;14: 22-27.
11. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006;15:167-172.
12. Lorgis V, Algros MP, Villanueva C, et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 2011;20:284-287.
13. Amendoeira N, Apostolikas N, Bellocq JP, et al. Quality assurance guidelines for pathjology, in: European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis (Perry N, Broeders M, deWolf C, Törnberg S, Holland R, vonKarsa L. (eds), 4th edn, Office of Official Publications of the European Communities: Luxembourg, 2006, pp288-289.
14. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric. Mammary Carcinoma Project. Hum Pathol 1992;23: 603-607.
15. Tuominen VJ, Ruotoistenmäki S, Viitanen A, et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12:R56.
16. Lehr HA, Hansen DA, Kussick S, et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol 1999;30:1314-1320.
17. Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994; 25:337-342.
18. Cavaliere A, Sidoni A, Scheibel M, et al. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 2005;218:117-121.
19. Start RD, Layton CM, Cross SS, et al. Reassessment of the rate of fixative diffusion. J Clin Pathol 1992; 451120-451121.
20. Koh H, Chung J. AMPK links energy status to cell structure and mitosis. Biochem Biophys Res Commun 2007;362:789-792.
21. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The active form of the metabolic sensor: AMPactivated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle 2009;8:2385-2398.
22. Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, et al. Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalpha Thr172) in human cancer cells. Cell Cycle 2009;8:788-791.
23. Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss working group of breast-and gynecopathologists. Plos One 2012;7:e37379.
24. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-e72.
25. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.